These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 465043)
21. Effect of antibodies to estrogen receptor on the binding of 3H-labeled antiestrogens and androstanediol in the uterus. Garcia M; Greene G; Rochefort H; Jensen EV Endocrinology; 1982 Apr; 110(4):1355-61. PubMed ID: 7060530 [TBL] [Abstract][Full Text] [Related]
22. Structure-activity relationship of antiestrogens: a study using triarylbutenone, benzofuran, and triarylfuran analogues as models for triarylethylenes and triarylpropenones. Durani N; Jain R; Saeed A; Dikshit DK; Durani S; Kapil RS J Med Chem; 1989 Aug; 32(8):1700-7. PubMed ID: 2754694 [TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2,3-diaryl-2H-1-benzopyrans. Sharma AP; Saeed A; Durani S; Kapil RS J Med Chem; 1990 Dec; 33(12):3216-22. PubMed ID: 2258907 [TBL] [Abstract][Full Text] [Related]
24. Cellular and molecular mechanism of action of antiestrogens. Rochefort H; Borgna JL; Evans E J Steroid Biochem; 1983 Jul; 19(1A):69-74. PubMed ID: 6887874 [TBL] [Abstract][Full Text] [Related]
25. Influence of alkyl chain ramification on estradiol receptor binding affinity and intrinsic activity of 1,2-dialkylated 1,2-bis(4- or 3-hydroxyphenyl)ethane estrogens and antiestrogens. Hartmann RW J Med Chem; 1986 Sep; 29(9):1668-74. PubMed ID: 3018243 [TBL] [Abstract][Full Text] [Related]
26. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799 [TBL] [Abstract][Full Text] [Related]
27. Physicochemical and genetic evidence for specific antiestrogen binding sites. Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477 [TBL] [Abstract][Full Text] [Related]
28. Antagonistic effect of triphenylethylenic antiestrogens on the association of estrogen receptor to calmodulin. Bouhoute A; Leclercq G Biochem Biophys Res Commun; 1992 May; 184(3):1432-40. PubMed ID: 1590802 [TBL] [Abstract][Full Text] [Related]
29. Estrogen-receptor--DNA interaction. Difference between activation by estrogen and antiestrogen. Evans E; Baskevitch PP; Rochefort H Eur J Biochem; 1982 Nov; 128(1):185-91. PubMed ID: 7173202 [TBL] [Abstract][Full Text] [Related]
30. Comparison of effects of 4-hydroxy tamoxifen and trilostane on oestrogen-regulated gene expression in MCF-7 cells: up-regulation of oestrogen receptor beta. Barker S; Malouitre SD; Glover HR; Puddefoot JR; Vinson GP J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):141-51. PubMed ID: 16806905 [TBL] [Abstract][Full Text] [Related]
31. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Suh N; Glasebrook AL; Palkowitz AD; Bryant HU; Burris LL; Starling JJ; Pearce HL; Williams C; Peer C; Wang Y; Sporn MB Cancer Res; 2001 Dec; 61(23):8412-5. PubMed ID: 11731420 [TBL] [Abstract][Full Text] [Related]
32. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Murphy CS; Parker CJ; McCague R; Jordan VC Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and antiestrogenic activity of the compounds related to the metabolites of (E)-4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]- 2-(4-isopropylphenyl)-1-butenyl]phenyl monophosphate (TAT-59) [corrected]. Ogawa K; Matsushita Y; Yamawaki I; Kaneda M; Shibata J; Toko T; Asao T Chem Pharm Bull (Tokyo); 1991 Apr; 39(4):911-6. PubMed ID: 1893497 [TBL] [Abstract][Full Text] [Related]
34. Synthesis and estrogen receptor affinity of 2,3-diarylindoles. Strohmeier J; von Angerer E Arch Pharm (Weinheim); 1987 May; 320(5):407-17. PubMed ID: 3606350 [No Abstract] [Full Text] [Related]
38. Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Miller MA; Katzenellenbogen BS Cancer Res; 1983 Jul; 43(7):3094-100. PubMed ID: 6850618 [No Abstract] [Full Text] [Related]
39. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer. Toko T; Shibata J; Nukatsuka M; Yamada Y Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952 [TBL] [Abstract][Full Text] [Related]
40. Binding of estradiol to whole prostatic DU-145 cells in the presence and absence of tamoxifen and acetylsalicylic acid. Viljoen TC; van Aswegen CH; du Plessis DJ Prostate; 1995 Sep; 27(3):160-5. PubMed ID: 7567695 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]